Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 319

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 319
---

for AD diagnostic tests is driven not only by AD patients, but also by the millions of aging baby boomers (approaching age 65 as well
as those in their 50s) considered as high risk for AD. The US population of 65+ year-olds is currently 58 million and is estimated
to reach 88.5 million by 2050.

Studies from Harvard and Tufts
Medical Center establish a high level of interest in early detection of AD and report that 66%–70% of respondents would like to
be screened for AD even if no treatment is available [Harvard study: Alzheimer’s Research & Therapy2013, 5:43;
telephone survey of 2,678 respondents from the US, France, Germany, Poland, Spain; Tufts study: Health Econ2012, 21:238;
internet survey of 1,463 US respondents]. The Special Report titled “American Perspectives on Early Detection of Alzheimer’s
Disease in the Era of Treatment” published by the Alzheimer’s Association in the first half of 2025 states: “Nearly
4 in 5 Americans surveyed would want to know if they had Alzheimer’s disease before having symptoms, or before those symptoms interfered
with their activities” (https://www.alz.org/getmedia/3d226bf2-0690-48d0-98ac-d790384f4ec2/alzheimers-facts-and-figures-special-report.pdf).

<div align='center'>183</div>

The survey also highlighted
reasons for seeking an early stage AD diagnosis:

Initial focus

Since DiamiR’s 24-microRNA
panel for risk assessment of Alzheimer’s disease, CogniMIR is now analytically validated, DiamiR’s miRNA panel
can be used to screen patients for MCI and AD clinical trials. In order to satisfy CLIA requirements, for analytical validation, DiamiR
performed studies to demonstrate the assay’s performance characteristics, including:

| ● | Accuracy |

| ● | Precision |

| ● | Reportable range |

| ● | Reference intervals/range |

The results of this validation
work were published in Journal Diagnostics, in July 2023: “Analytical Validation of a Novel MicroRNA Panel for Risk Stratification
of Cognitive Impairment”. Kunwar et.al, Diagnostics 2023, 13, 2170. DiamiR believes its test can be launched as an LDT under current
FDA